PureTech Gains FDA Fast Track for LYT-200 in HR-MDS
LONDON — September 21, 2026 PureTech Health announced the successful completion of an End-of-Phase 1 meeting with the U.S....
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
LONDON — September 21, 2026 PureTech Health announced the successful completion of an End-of-Phase 1 meeting with the U.S....
BALLERUP, DENMARK, August 18, 2026 LEO Pharma has entered into an agreement to acquire worldwide rights to dersimelagon from...
LONDON, August 18, 2026 Smith+Nephew and Imperial College London have launched a new five-year partnership to accelerate innovation in...
BEIJING, August 18, 2026 InnoCare Pharma announced that China’s Center for Drug Evaluation (CDE) of the National Medical Products...
PARIS, July 10, 2026 AB Science announced a major strategic update to its clinical development pipeline, confirming that it...
HONG KONG, May 15, 2026 Akeso, Inc. announced positive Phase II clinical trial results for ligufalimab (AK117) in frontline...
MAINZ, Germany, November 3, 2025 — BioNTech SE (Nasdaq: BNTX) reported its third quarter 2025 financial results, highlighting significant...
SAN DIEGO and TORONTO, November 3, 2025 — Aptose Biosciences Inc. (TSX: APS), a clinical-stage precision oncology company, announced...
